Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Defining the Contribution of CYP1A1 and CYP1A2 to Drug Metabolism Using Humanized CYP1A1/1A2 and Cyp1a1/Cyp1a2 Knockout Mice.

Drug metabolism and disposition: the biological fate of chemicals·2019
Same author

An Extensively Humanized Mouse Model to Predict Pathways of Drug Disposition and Drug/Drug Interactions, and to Facilitate Design of Clinical Trials.

Drug metabolism and disposition: the biological fate of chemicals·2019
Same author

MicroRNA-224 is associated with colorectal cancer progression and response to 5-fluorouracil-based chemotherapy by KRAS-dependent and -independent mechanisms.

British journal of cancer·2015
Same author

Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines.

British journal of cancer·2014
Same author

Immunodetection of proteins by Western blotting.

Methods in molecular biology (Clifton, N.J.)·2012
Same author

Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer.

British journal of cancer·2012

Related Experiment Video

Updated: May 31, 2026

Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology
11:20

Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology

Published on: March 21, 2018

Pyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human

S Weidlich1, K Walsh, D Crowther

  • 1Biomedical Research Institute, University of Dundee, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK.

British Journal of Cancer
|June 30, 2011
PubMed
Summary

Quantitative pyrosequencing improves detection of low-frequency mutations in colorectal cancer, aiding assessment of tumor mutation burden for targeted therapies like cetuximab.

More Related Videos

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Related Experiment Videos

Last Updated: May 31, 2026

Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology
11:20

Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology

Published on: March 21, 2018

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Cetuximab (Erbitux) is a monoclonal antibody for metastatic colorectal cancer.
  • Treatment response to cetuximab depends on Kirsten-Ras (K-Ras) mutation status.
  • Tumor-specific K-Ras mutations often predict non-response to cetuximab.

Purpose of the Study:

  • To assess tumor mutation burden in colorectal cancer.
  • To evaluate the role of K-Ras, B-Raf, and PIK3CA mutations in cetuximab response.
  • To compare dideoxy and pyrosequencing methods for mutation detection.

Main Methods:

  • Identified mutations in K-Ras, B-Raf, and PIK3CA using dideoxy and quantitative pyrosequencing.
  • Analyzed a cohort of 102 unselected colorectal tumors.
  • Correlated pyrosequencing mutation calls with clinico-pathological parameters.

Main Results:

  • Quantitative pyrosequencing identified a 13.7% increase in mutation burden compared to dideoxy sequencing.
  • Low-frequency mutations (<30% mutation burden) were detected by pyrosequencing but not dideoxy sequencing.
  • K-Ras and B-Raf mutations were mutually exclusive and linked to advanced tumor phenotypes.

Conclusions:

  • Pyrosequencing enables accurate assessment of tumor mutation burden by detecting low-frequency mutations.
  • Quantitative mutation burden assessment can refine understanding of colorectal cancer pathogenesis and progression.
  • Improved patient selection for targeted therapies may result from quantitative mutation analysis.